Company intelligence / Profile preview

Placer Biosciences

Ownership: Private
Development stage: Preclinical

Overview

Placer Biosciences is a preclinical-stage biotech company developing novel, non-psychoactive cannabinoid prodrugs and engineered enzymes as potential treatments for inflammatory bowel diseases. The company recently acquired the legacy cannabinoid drug development assets of Graphium Biosciences from Range Impact, including intellectual property and early-stage programs targeting gastrointestinal inflammation. No clinical results have been reported to date.[4][6][8]

Therapeutic areas: Gastroenterology
Modalities: Cannabinoid prodrugsNovel small molecules (including enzyme-based therapeutics)[1][3]
Industry: Biotech

Partnerships

Range Impact retains a minority equity interest via warrants as part of the asset sale agreement; no major pharma partnerships disclosed yet.[6][7]

Beyond the preview

Go deeper on Placer Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Placer Biosciences.

Explore the full profile